“The capacity to provide cleaning solutions made from recycled carbon with outstanding effectiveness is a distinguishing factor that significantly influences the purchasing decisions of household consumers,” said Farooq Alam, Global Strategic Marketing Director, Dow Home Care. “EcoSense™ 2470 underscores our dedication to eco-conscious surfactant manufacturing, serving as the gateway to a sustainable future. It sends a resounding message to both home care brand owners and consumers that sustainability and superior performance work hand-in-hand harmoniously.”

“There is enough carbon above ground to make all the things we need,” said Jennifer Holmgren, CEO of LanzaTech. “We have been active in the ethoxylates space for several years, converting ethanol to surfactant ingredients, and with now Dow, our collaboration will enable us to greatly expand our reach in this market."

Bringing a new drug product to market can be a major challenge when it comes to guiding the late-stage development through to commercial readiness and launch. In fact, this is often considered one of the most impactful milestones of any drug program, because it culminates years of development work.

It usually is during late-stage development where there is a mindset shift from developing a drug product, to commercializing it. Since timing is a crucial factor, decisive and focused launch management is required and involves a dedicated and experienced team to coordinate all necessary process steps. A successful first commercial production can be achieved in a predetermined timeline by following a thorough step-by-step approach.

The biopharma product launch landscape is very diverse, and as such, the needs of each product to reach the market can vary significantly. To effectively establish a plan for launch management, the Contract Development and Manufacturing Organization (CDMO) partner needs to work closely with the customer to decide on the product-specific process.

Part of the launch is designing a tried-and-true methodology to meet the specific needs of each molecule to bring both, a small batch as well as a blockbuster drug to market. Throughout the launch management process, the team is working against the launch date with the intentions to follow the best product implementation strategy for commercial market supply.

To learn more about the 5-step process, click here.

Vetter, one of the world’s leading fill and finish CDMOs for injectables, established a 5-step process for maximum efficiency when bringing a drug product to commercialization. This process offers a tried-and-true methodology for getting a small batch as well as blockbuster drug product to market.

Nevertheless, this process requires continued adaptation and adjustment to align with environmental factors. As a result of these external obstacles, Vetter bases success on a plannable and structured process, that provides reliability for customers on the launch management timeline set at the start of the journey. 

This reliable step-by-step process has supported customers’ success, big and small, for both startup biotech companies and pharma giants, and will be further adapted to continue doing so in the future.

Northwestern University continued its multiyear ascent as a research powerhouse, once again demonstrating exceptional growth in fiscal year 2023. For the first time, the University joins a highly exclusive group of peers whose annual research funding is $1 billion or more.

This achievement extends a decade-long growth trajectory for Northwestern’s research enterprise. At the close of the fiscal year on Aug. 31, the University exceeded $1 billion in annual research funding for the first time, the results fueled by an 9% year-over-year increase in funding from various sources, including federal agencies, foundations and corporate entities. The number of awards received for FY23 totaled 3,888, an increase of 293 (8.2%) from the previous year. Overall research funding for Northwestern has grown 83% since 2013. This year’s total was $1.0087 billion.

To learn more about NU research, click here.

“Northwestern’s phenomenal strengths as a research leader are evidenced by the high-impact work our scientists and scholars produce year-round,” said Milan Mrksich, vice president for research. “That impact is our primary focus. Still, reaching this new level of funding is significant, as doing so is a powerful sign of our continued success in producing knowledge and innovation that makes the world a better place.”